 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Medlere Limited |
| Street 1: | 53 Whateleys Drive Kenilworth Warwickshire CV8 2GY |
| Street 2: | 291 Brighton Road South Croydon United Kingdom Cr2 6Eq |
| City: | London |
| Province: | |
| Post Code: | |
| Country: | United Kingdom of Great Britain and Northern Ireland |
| Phone: | +447565748991 |
| Organization Email: | info@medlere.com |
| Web Site: | http://www.medlere.com |
| Other Online Presence: | |
|
|
||||||||||||||||||||||||||||
General Information | |
| Board Constituency: | None |
| Is your organization legally registered in your country: | Yes |
| If yes, please enter your registration number: | 14731686 |
| Organization Type - Primary: | Private Sector |
| Organization Type - Secondary: | Marketing |
| Organization Description: | |
| As a manufacturer of in vitro diagnostic (IVD) products in the UK, our mission is to develop and produce innovative diagnostic solutions to address pressing healthcare needs, including the diagnosis and management of tuberculosis (TB). Our main focus is on creating reliable, accurate, and accessible diagnostic tools that contribute to improving patient outcomes and public health. We are particularly interested in TB due to its significant global burden and the pressing need for improved diagnostic technologies. TB remains a major public health challenge worldwide, with millions of new cases and deaths reported each year. Early and accurate diagnosis of TB is essential for timely initiation of treatment, reducing transmission, and preventing the development of drug-resistant strains. As a manufacturer of IVD products, we are committed to advancing TB diagnostics through the following initiatives: Development of Rapid Diagnostic Tests: We invest in research and development to create rapid and point-of-care TB diagnostic tests that can provide timely results within minutes or hours. These tests aim to improve diagnostic accuracy and accessibility, especially in resource-limited settings where TB is most prevalent. Innovation in Molecular Diagnostics: We leverage molecular biology techniques to develop nucleic acid-based assays for the detection of TB infection and drug resistance. These assays offer high sensitivity and specificity, enabling the rapid identification of TB cases and guiding appropriate treatment decisions. Quality Assurance and Regulatory Compliance: We adhere to stringent quality control measures and regulatory standards to ensure the safety, efficacy, and reliability of our TB diagnostic products. This includes compliance with regulations set forth by the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and other relevant regulatory bodies. Collaboration and Partnerships: We collaborate with healthcare providers, researchers, public health agencies, and internat |
|
| Do you know about the UNHLM declaration: | Yes |
Specializations / Areas of Work | |
|
Research and Development Working on Key Populations related to TB |
Other Organization Information | |
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 11 - 25 |
| Number of part-time staff who are directly involved with TB: | 11 - 25 |
| Number of volunteers who are directly involved with TB: | 26 - 50 |
| How did you hear about the Stop TB Partnership: | Internet search |
| If you were informed or referred by another partner of the Stop TB Partnership please tell us who: | Danny |
| Why do you wish join the Stop TB Partnership: | Network with other partners |
| Are you a member of a Stop TB national partnership: | No |
| Are you in contact with your national TB programme: | No |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Offering advanced technology to diagnose patients with TB | |
Geographical Reach | |
| Which country is your headquarters located in: | China |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
China |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
New Diagnostics: Develop and distribute advanced diagnostic products for detecting TB. We plan to develop a diagnostic tool that can be used to detect TB and HIV simultaneously. What's more, we are going to work with some companies that have AI CAD software and help them sell their products to some people who need this product most around the world. |
|
Declaration | |
| Declaration of interests: No conflicts of interest were delacred. | |
| Application date: | March 21, 2024 |
| Last updated: | April 1, 2025 |